Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 22 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

9%

2 trials in Phase 3/4

Results Transparency

6%

1 of 16 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

15Total
Not Applicable (10)
P 1 (3)
P 3 (2)

Trial Status

Completed16
Not Yet Recruiting2
Unknown2
Suspended1
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 16 completed trials

Clinical Trials (22)

Showing 20 of 20 trials
NCT06507813Phase 3Completed

Safety and Efficacy of ADC189 in Children 2-11 Years Old With Influenza

NCT06008457Completed

Evaluation of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit

NCT06928129Not ApplicableNot Yet Recruiting

Clinical Feasibility of the BinaxNOW™ COVID-19/Flu A&B Combo in the Southern Hemisphere

NCT06622590Phase 1Active Not Recruiting

Phase I Clinical Trial of Quadrivalent Influenza Virus Split Vaccine

NCT06485401Phase 1Completed

To Compare the Safety and PK/ PD Characteristics of ADC189 Between Hepatic Impairment and Normal Hepatic Function Subjects

NCT04471038Phase 1Completed

Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants

NCT06124638Not ApplicableCompleted

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel to Support Home Use

NCT05897515Not ApplicableCompleted

LIAISON NES Influenza (FLU) A/B & Coronavirus Disease 2019 (COVID-19) Clinical Agreement in Australia

NCT06392451Not ApplicableNot Yet Recruiting

LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia

NCT05727202Completed

Project STARFISH - PRJ0002679

NCT06385821Phase 3Completed

A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus

NCT04782336Not ApplicableSuspended

Sample Collection Study to Aid Evaluation of an Influenza A/B, Respiratory Syncytial Virus & COVID-19 Virus POC Test

NCT05630365Not ApplicableCompleted

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Product Using Mid-Turbinate Nasal Swabs

NCT05715515Not ApplicableCompleted

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Device and the Panbio™ COVID-19/Flu A&B Rapid Panel Self-Test Device

NCT05354115Not ApplicableCompleted

Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel.

NCT05268939Not ApplicableCompleted

Performance Evaluation of the LumiraDx SARS-CoV-2 & FLU A/B and SARS-CoV-2 & RSV Tests for Aid in the Assessment of COVID-19

NCT05928507Unknown

FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol

NCT05163730Not ApplicableCompleted

Clinical Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel

NCT03895268Unknown

Influenza A+B Test Kit Performance Study

NCT04245800Completed

Home Testing of Respiratory Illness

Scroll to load more

Research Network

Activity Timeline